| Literature DB >> 33008412 |
Giorgio Cartechini1,2, Francesco Fracchiolla3, Loris Menegotti4, Emanuele Scifoni2, Chiara La Tessa1,2, Marco Schwarz2,3, Paolo Farace3, Francesco Tommasino5,6.
Abstract
PURPOSE: Proton pencil beam scanning (PBS) represents an interesting option for the treatment of breast cancer (BC) patients with nodal involvement. Here we compare tangential 3D-CRT and VMAT to PBS proton therapy (PT) in terms of secondary cancer risk (SCR) for the lungs and for contralateral breast.Entities:
Keywords: Breast cancer; Proton therapy; Secondary cancer risk; Tangential 3D-CRT; VMAT
Mesh:
Year: 2020 PMID: 33008412 PMCID: PMC7532613 DOI: 10.1186/s13014-020-01671-8
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Fig. 1Summary of the dose distributions obtained with the different irradiation techniques. A representative Group 1 patient receiving PT is shown in a, while the corresponding 3D-CRT plan is displayed in b. Concerning Group 2, a typical dose distribution with FB treatment is shown for PT (c) and VMAT (d). The corresponding DIBH plan is finally reported for PT (e) and VMAT (f). The limited dependence on patient setup (FB vs DIBH) can be appreciated
Dosimetric parameters for the OARs included in the SCR estimation for the patients included in the analysis
| FB | DIBH | |||||
|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 2 | ||||
| PT | Tangential 3D-CRT | PT | VMAT | PT | VMAT | |
| Average dose (Gy) | ||||||
| Ipsilateral lung | 5.9 ± 2.1 | 11.5 ± 1.1 | 8.4 ± 0.3 | 16.4 ± 1.6 | 7.4 ± 0.8 | 14.6 ± 0.9 |
| Contralateral lung | 0.08 ± 0.10 | 0.6 ± 0.1 | 0.3 ± 0.1 | 7.3 ± 0.4 | 0.15 ± 0.02 | 6.2 ± 0.3 |
| Contralateral breast | 0.08 ± 0.03 | 0.9 ± 0.1 | 0.09 ± 0.02 | 4.7 ± 0.3 | 0.07 ± 0.01 | 4.8 ± 0.3 |
The data are presented as mean ± standard error of the mean (SEM, n = 5)
Fig. 2Cumulative DVHs obtained averaging over the patients included in the study for Group 1 (left column) and Group 2 (right column). DVHs are shown for the ipsilateral lung (upper panel), contralateral lung (middle panel) and contralateral breast (lower panel). The different planning techniques are shown for each OAR. Please notice that different scales are adopted for the X-axis
Average EAR expressed in number of cases per 10,000 persons per year for Group 1 and Group 2
| EAR30-70 (number of cases per 10,000 persons per year) | ||||||
|---|---|---|---|---|---|---|
| 3D-CRT | PT | |||||
| Linear | Lin-exp | Lin-plat | Linear | Lin-exp | Lin-plat | |
| Group 1 | ||||||
| Ipsilateral lung | 85 ± 18 | 27 ± 3 | 25 ± 3 | 44 ± 22 | 16 ± 7 | 14 ± 6 |
| Contralateral lung | 3 ± 1 | 3 ± 1 | 3 ± 1 | 1 ± 1 | 0 ± 1 | 0 ± 1 |
| Contralateral breast | 7 ± 3 | 6 ± 2 | 6 ± 2 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
EAR are reported for the three OARs considered, according to the linear, linear-exponential and linear-plateau models. Uncertainty indicates the standard deviation
Fig. 3EAR difference as a function of the age of exposure (EAR30–70–EAR50–70) for the single patients included in the analysis. The EAR difference is shown for the contralateral breast for Group 1 patients treated with tangential 3D-CRT vs PT (top panel) and for Group 2 patients treated with VMAT versus PT in the case of FB (middle panel) and DIBH (bottom panel)